ASELAGE STEVE 4
4 · Travere Therapeutics, Inc. · Filed May 12, 2022
Insider Transaction Report
Form 4
ASELAGE STEVE
Director
Transactions
- Sale
Common Stock
2022-05-11$21.92/sh−2,575$56,457→ 146,919 total
Footnotes (1)
- [F1]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.